European Innovation Council

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in developing advanced thermotherapy systems for treating head and neck cancers. The company's proprietary technology incorporates localized heating through an integrated microwave system, complemented by interactive software, which allows healthcare professionals to enhance traditional cancer treatments such as radiotherapy and chemotherapy. This innovative approach aims to improve patient outcomes and quality of life by mitigating the toxic effects commonly associated with standard therapies. Sensius has successfully treated seventy patients with its device, achieving a complete response rate of 81.8% at 12 weeks post-treatment. Currently, the company is working towards obtaining CE marking for its device, with significant interest from potential buyers, as it also plans to expand its application to other cancer types in the future.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in developing advanced thermotherapy systems for treating head and neck cancers. The company's proprietary technology incorporates localized heating through an integrated microwave system, complemented by interactive software, which allows healthcare professionals to enhance traditional cancer treatments such as radiotherapy and chemotherapy. This innovative approach aims to improve patient outcomes and quality of life by mitigating the toxic effects commonly associated with standard therapies. Sensius has successfully treated seventy patients with its device, achieving a complete response rate of 81.8% at 12 weeks post-treatment. Currently, the company is working towards obtaining CE marking for its device, with significant interest from potential buyers, as it also plans to expand its application to other cancer types in the future.

Allero Therapeutics B.V. is a biopharmaceutical company based in Rotterdam, the Netherlands, founded in 2016. The company specializes in developing programmed immunotherapies aimed at treating immune-mediated disorders. Utilizing its Specific Oromucosal Immunotherapy (SOMIT) platform, Allero Therapeutics focuses on restoring immune tolerance through the targeted delivery of antigen-specific therapies. This innovative approach is based on research conducted by the founders and their collaborators, enabling the induction of long-lasting antigen-specific tolerance. The technology is designed to address a variety of clinical indications with significant unmet medical needs, particularly in the fields of allergic and autoimmune diseases.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in developing advanced thermotherapy systems for treating head and neck cancers. The company's proprietary technology incorporates localized heating through an integrated microwave system, complemented by interactive software, which allows healthcare professionals to enhance traditional cancer treatments such as radiotherapy and chemotherapy. This innovative approach aims to improve patient outcomes and quality of life by mitigating the toxic effects commonly associated with standard therapies. Sensius has successfully treated seventy patients with its device, achieving a complete response rate of 81.8% at 12 weeks post-treatment. Currently, the company is working towards obtaining CE marking for its device, with significant interest from potential buyers, as it also plans to expand its application to other cancer types in the future.